LifeGuide

A newly approved anti-diarrheal agent seeks to counter side effects of HAART by Chael Needle Recently, the FDA approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for...

What were the top five HCV-related stories of 2012? by Larry Buhl There were many important news stories about hepatitis in 2012. In this column we...

Walgreens dispenses vital support through HIV-specialized pharmacies Wellness Watch by Chael Needle Individuals living with HIV/AIDS and in treatment may not know that one pharmacy may...

HEPCredefined.com provides a portal for learning about HCV Hep Talk by Larry Buhl It’s been said that the hepatitis C virus (HCV) is a silent killer,...

Stronger Punch? Monoclonal antibodies provide new hope for easier dosing by Jeannie Wraight With multi-drug, once-a-day therapies now available for use, the push for additional easier to...

A not-for-profit biotech helps energize the future of TB vaccine R&D by Chael Needle According to the World Health Organization, tuberculosis is the most common illness...

Finger on the Pulse The UFO Plan meets young IV drug users where they are by Larry Buhl Hepatitis prevention and treatment efforts depend on outreach. For...

Not So Complicated Alisson Sombredero, MD, offers to physicians compelling approaches to HIV care by Chael Needle Alisson Sombredero, MD, is more than two months into her...

Six drugs promise to further revolutionize HCV treatments by Larry Buhl The hepatitis C (HCV) treatment revolution is a little more than a year old, but...

HCV advocate, author & nurse Lucinda Porter offers perspectives on care by Larry Buhl Lucinda Porter, RN, understands viral hepatitis from both sides: as a healthcare practitioner and...